,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1195,1,2,,48415779,2747,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
1,1469,1,1,,26755692,2747,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
2,1471,2,1,,26755692,2747,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
3,1479,1,2,,26755692,2747,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
4,1490,2,1,,26755692,2747,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
5,1688,1,1,,26755692,2747,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
6,1766,1,1,,26755692,2747,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
7,1766,1,1,,26755692,2747,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
8,1768,1,1,,26755692,2747,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
9,1768,1,1,,26755692,2747,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
10,2528,1,2,,26755692,2747,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
11,2546,1,1,,26755692,2747,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
12,2551,1,1,,26755692,2747,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
13,2660,1,1,,90341191,2747,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
14,2662,2,1,,26755692,2747,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
15,2666,1,1,,90341191,2747,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
16,2667,1,1,,90341191,2747,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
17,2668,1,1,,90341191,2747,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
18,22293,4,4,,103293640,2747,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
19,26304,4,4,,103293640,2747,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
20,29359,3,3,,103293640,2747,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
21,29811,4,3,,103293640,2747,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
22,240820,9,2,,103293640,2747,Active,,,8.8,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
23,411793,6,2,,103293640,2747,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein,Other,19108654.0,
24,425652,7,2,,103293640,2747,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
25,425653,7,2,,103293640,2747,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
26,444050,7,1,,103293640,2747,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
27,444051,6,2,,103293640,2747,Unspecified,,,,,Total clearance in human,Other,20070106.0,
28,444052,6,2,,103293640,2747,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
29,444053,6,2,,103293640,2747,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
30,444054,6,1,,103293640,2747,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
31,444055,3,3,,103293640,2747,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
32,444056,3,3,,103293640,2747,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
33,444057,3,3,,103293640,2747,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
34,444058,6,2,,103293640,2747,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
35,463106,1,2,,90341191,2747,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
36,485290,1,1,,26755692,2747,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
37,485295,1,2,,90341191,2747,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
38,485297,1,1,,90341191,2747,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
39,485298,1,1,,90341191,2747,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
40,485313,1,2,,90341191,2747,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
41,485342,1,2,,90341191,2747,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
42,485345,1,2,,90341191,2747,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
43,485366,1,2,,90341191,2747,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
44,485368,1,2,,90341191,2747,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
45,488772,1,1,,90341191,2747,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
46,488773,1,2,,90341191,2747,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
47,488816,1,1,,90341191,2747,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
48,488837,1,1,,90341191,2747,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
49,488949,1,2,,90341191,2747,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
50,488953,1,1,,90341191,2747,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
51,488978,1,1,,90341191,2747,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
52,488981,1,1,,90341191,2747,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
53,488982,1,1,,90341191,2747,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
54,488983,1,1,,90341191,2747,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
55,492961,1,1,,26755692,2747,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
56,493017,1,1,,103858535,2747,Unspecified,,3762.0,,,Wombat Data for BeliefDocking,Other,15324906.0,
57,493106,1,1,,90341191,2747,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
58,493107,1,1,,90341191,2747,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
59,493153,1,1,,90341191,2747,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
60,493153,1,1,,90341191,2747,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
61,493164,1,2,,90341191,2747,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
62,493164,1,2,,90341191,2747,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
63,493164,1,2,,90341191,2747,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
64,504327,1,1,,26755692,2747,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
65,504327,1,1,,90341191,2747,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
66,504332,1,1,,26755692,2747,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
67,504332,1,1,,90341191,2747,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
68,504536,1,1,,90341191,2747,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
69,504547,1,1,,90341191,2747,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
70,504548,1,2,,90341191,2747,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
71,504749,1,3,,26755692,2747,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
72,504749,1,3,1.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
73,504749,1,3,2.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
74,504749,1,3,3.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
75,504749,1,3,4.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
76,504749,1,3,5.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
77,504749,1,3,6.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
78,504749,1,3,7.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
79,504749,1,3,8.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
80,504749,1,3,9.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
81,504749,1,3,10.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
82,504749,1,3,11.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
83,504749,1,3,12.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
84,504749,1,3,13.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
85,504749,1,3,14.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
86,504749,1,3,15.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
87,504749,1,3,16.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
88,504749,1,3,17.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
89,504749,1,3,18.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
90,504749,1,3,19.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
91,504749,1,3,20.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
92,504749,1,3,21.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
93,504749,1,3,22.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
94,504749,1,3,23.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
95,504749,1,3,24.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
96,504749,1,3,25.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
97,504749,1,3,26.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
98,504749,1,3,27.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
99,504749,1,3,28.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
100,504749,1,3,29.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
101,504749,1,3,30.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
102,504749,1,3,31.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
103,504749,1,3,32.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
104,504749,1,3,33.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
105,504749,1,3,34.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
106,504749,1,3,35.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
107,504749,1,3,36.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
108,504749,1,3,37.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
109,504749,1,3,38.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
110,504749,1,3,39.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
111,504749,1,3,40.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
112,504749,1,3,41.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
113,504749,1,3,42.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
114,504749,1,3,43.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
115,504749,1,3,44.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
116,504749,1,3,45.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
117,504749,1,3,46.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
118,504749,1,3,47.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
119,504749,1,3,48.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
120,504749,1,3,49.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
121,504749,1,3,50.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
122,504749,1,3,51.0,26755692,2747,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
123,504749,1,3,52.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
124,504749,1,3,53.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
125,504749,1,3,54.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
126,504749,1,3,55.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
127,504749,1,3,56.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
128,504749,1,3,57.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
129,504749,1,3,58.0,26755692,2747,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
130,504749,1,3,59.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
131,504749,1,3,60.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
132,504749,1,3,61.0,26755692,2747,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
133,504810,1,2,,90341191,2747,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
134,504812,1,2,,90341191,2747,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
135,504832,1,1,,26755692,2747,Inconclusive,,,15.1014,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
136,504834,1,1,,26755692,2747,Active,,,13.4591,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
137,504836,1,2,,90341191,2747,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
138,504845,1,1,,90341191,2747,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
139,504847,1,1,,26755692,2747,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
140,504847,1,1,,90341191,2747,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
141,504865,1,1,,26755692,2747,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
142,504865,1,1,,90341191,2747,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
143,540209,4,3,,103293640,2747,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
144,540210,4,3,,103293640,2747,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
145,540211,2,5,,103293640,2747,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
146,540212,4,3,,103293640,2747,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
147,540213,4,3,,103293640,2747,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
148,540256,1,2,,90341191,2747,Inconclusive,,,32.6294,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
149,540276,1,2,,26755692,2747,Inconclusive,420597.0,,12.99,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
150,540276,1,2,,90341191,2747,Inconclusive,420597.0,,12.99,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
151,588349,1,1,,90341191,2747,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
152,588378,1,1,,90341191,2747,Inconclusive,171543895.0,6311.0,25.1189,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
153,588453,1,1,,90341191,2747,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
154,588456,1,1,,90341191,2747,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
155,588579,1,1,,26755692,2747,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
156,588579,1,1,,90341191,2747,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
157,588795,1,1,,90341191,2747,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
158,589039,1,10,,103293640,2747,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
159,602332,1,1,,26755692,2747,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
160,602332,1,1,,90341191,2747,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
161,624030,1,2,,26755692,2747,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
162,624031,1,2,,26755692,2747,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
163,624032,1,2,,26755692,2747,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
164,624044,1,2,,26755692,2747,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
165,624146,1,1,,90341191,2747,Inactive,71051501.0,2744.0,35.4813,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
166,624147,1,1,,90341191,2747,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
167,624148,1,2,,90341191,2747,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
168,624149,1,1,,90341191,2747,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
169,624170,1,1,,26755692,2747,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
170,624172,1,1,,26755692,2747,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
171,624173,1,3,,26755692,2747,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
172,624296,1,1,,26755692,2747,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
173,624297,1,1,,26755692,2747,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
174,624455,1,1,,90341191,2747,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
175,651635,1,3,,90341191,2747,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
176,652106,1,1,,90341191,2747,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
177,720538,1,2,,90341191,2747,Inconclusive,220983390.0,410.0,0.1901,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
178,720559,1,2,,90341191,2747,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
179,720572,1,2,,90341191,2747,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
180,720573,1,2,,90341191,2747,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
181,743205,1,1,,90341191,2747,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
182,743205,1,1,,90341191,2747,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
183,743206,1,1,,90341191,2747,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
184,743206,1,1,,90341191,2747,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
185,743207,1,1,,90341191,2747,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
186,743207,1,1,,90341191,2747,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
187,743244,1,1,,90341191,2747,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
188,1079931,1,1,,103293640,2747,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
189,1079932,1,1,,103293640,2747,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
190,1079933,1,1,,103293640,2747,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
191,1079934,1,1,,103293640,2747,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
192,1079935,1,1,,103293640,2747,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
193,1079936,1,1,,103293640,2747,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
194,1079937,1,1,,103293640,2747,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
195,1079938,1,1,,103293640,2747,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
196,1079939,1,1,,103293640,2747,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
197,1079940,1,1,,103293640,2747,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
198,1079941,1,1,,103293640,2747,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
199,1079942,1,1,,103293640,2747,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
200,1079943,1,1,,103293640,2747,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
201,1079944,1,1,,103293640,2747,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
202,1079945,1,1,,103293640,2747,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
203,1079946,1,1,,103293640,2747,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
204,1079947,1,1,,103293640,2747,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
205,1079948,1,1,,103293640,2747,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
206,1079949,1,1,,103293640,2747,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
207,1159620,1,1,,103293640,2747,Active,,,,,Summary of drug indications.,Other,,
208,1207151,1,1,,103293640,2747,Active,,,7.8,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
209,1207181,1,1,,103293640,2747,Active,,,30.0,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
210,1207210,1,1,,103293640,2747,Active,,,22.6,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
211,1207241,1,2,,103293640,2747,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
212,1207623,1,2,,103293640,2747,Active,5921694.0,100135490.0,14.4,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
213,1207624,1,2,,103293640,2747,Active,5921694.0,100135490.0,30.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
214,1207625,1,2,,103293640,2747,Active,5921694.0,100135490.0,14.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
215,1224859,2,1,,90341191,2747,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
216,1259416,1,2,,375178128,2747,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
217,1259421,1,1,,375178128,2747,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
218,1259423,1,2,,354793459,2747,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
